Glioblastoma – VJRegenMed

Novel oncolytic Ad6 vectors for cancer therapy

admin_vjr_user — Thu, 03 Jun 2021 16:50:51 +0000

Margarita Romanenko, PhD, University of Minnesota, Minneapolis, MN, describes a novel adenovirus serotype 6 (Ad6) oncolytic vector currently being investigated for the potential treatment of different cancer types such as glioblastoma and breast cancer. With the aim of enhancing anti-tumor efficacy, a recombinant Ad6 vector was developed with the tumor-specific human telomerase reverse transcriptase (hTERT) promoter and the expression of the human granulocyte macrophage colony-stimulating factor (GMCSF). Further preclinical study is required to further evaluate the potential of the Ad6-hTERT-GMCSF vector as an oncolytic vector and a vaccine. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

Unmet needs in the treatment of glioblastoma

admin_vjr_user — Wed, 19 Aug 2020 16:20:19 +0000

Khaled Sanbar, MD, PhD, of Johns Hopkins Hospital, Baltimore, MD, highlights the challenges faced in the treatment of glioblastoma and the potential of CAR T-cell therapy in treating this highly malignant brain tumor. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Barriers to CAR-T for glioblastoma

admin_vjr_user — Wed, 19 Aug 2020 16:20:19 +0000

Khaled Sanbar, MD, PhD, Johns Hopkins Hospital, Baltimore, MD, explores challenges in implementing CAR T-cell therapies for glioblastoma routine treatment, including administration, antigen heterogeneity of tumors, and persistence of the CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).